Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Gori S, et al. Among authors: gamucci t. Ann Oncol. 2012 Jun;23(6):1436-41. doi: 10.1093/annonc/mdr474. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039084 Free article.
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
Gori S, Clavarezza M, Siena S, Foglietta J, Tarenzi E, Giordano M, Molino A, Graiff C, Fusco V, Alabiso O, Baldini E, Gamucci T, Altavilla G, Dondi D, Venturini M. Gori S, et al. Among authors: gamucci t. BMC Cancer. 2012 Apr 30;12:158. doi: 10.1186/1471-2407-12-158. BMC Cancer. 2012. PMID: 22545982 Free PMC article.
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, Gori S, Gamucci T, Passalacqua R, Gnoni R, Moretti G, Boni C. Bisagni G, et al. Among authors: gamucci t. Cancer Chemother Pharmacol. 2013 Apr;71(4):1051-7. doi: 10.1007/s00280-013-2100-6. Epub 2013 Feb 3. Cancer Chemother Pharmacol. 2013. PMID: 23377310 Clinical Trial.
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I, Franco D, Ruggeri EM. Moscetti L, et al. Among authors: gamucci t. Invest New Drugs. 2013 Aug;31(4):1035-43. doi: 10.1007/s10637-013-9936-9. Epub 2013 Feb 17. Invest New Drugs. 2013. PMID: 23417697
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Natoli C, et al. Among authors: gamucci t. J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20. J Cancer Res Clin Oncol. 2013. PMID: 23604446 Free PMC article.
153 results